News Image

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Provided By GlobeNewswire

Last update: Feb 28, 2024

- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade -

Read more at globenewswire.com

SENSEI BIOTHERAPEUTICS INC

NASDAQ:SNSE (7/11/2025, 8:00:02 PM)

8.1654

-0.93 (-10.27%)



Find more stocks in the Stock Screener

Follow ChartMill for more